R.C. Hillig

Medicine · Health Sciences

22h-index2.4kcitations98works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(17), HER2/EGFR in Cancer Research(17), Protein Kinase Regulation and GTPase Signaling(10), Enzyme Structure and Function(10), Computational Drug Discovery Methods(9)

Publications98 total

Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S6 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S8 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Polo-like kinase 1–inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approach
Acta Crystallographica Section D Structural Biology·2025Open Access
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Cancer Discovery·2025· 4 citedOpen Access
CRYSTAL STRUCTURE OF WILD-TYPE PLK1 KINASE DOMAIN IN COMPLEX WITH THIAZOLIDINONE INHIBITOR COMPOUND 1 AND A SELECTIVE DARPIN
2025
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran <i>In Vivo</i>-Active KAT6AB Inhibitor
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Surface-mutagenesis strategies to enable structural biology crystallization platforms
Acta Crystallographica Section D Structural Biology·2024· 4 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Volker Badock(12), Dieter Moosmayer(8), Roland Neuhaus(8), A. Hilpmann(7), Stefan Gradl(6), Hans Briem(6), Benjamin Bader(6), Ingo V. Hartung(6), Ursula Egner(6), Katja Zimmermann(5), Jens Schroeder(5), Ulf Boemer(5), Kirstin Petersen(5), Knut Eis(5), Martin Hülsmeyer(5), Wolfram Saenger(5), Uwe Eberspaecher(5), Volker Schulze(5), Anne Mengel(5), Sven Christian(4)